Mark Chapman
Contributor since: 2013
Why I Sold Antares Pharma
The Sum Of All Fears For This Small Pharma
Catabasis: Breakthrough In Duchenne And Case For Accelerated Approval
Aerie Pharma: Bullish Thesis Intact
Domino's And Papa John's Face Major Threat As Pizza Industry Is Set To Change
Unilife Provides Update - Any Hope Left?
Aerie Pharma: 80% Upside While The Moon Shot Awaits
Nuance: Icahn And The Selloff
Sell ACADIA Pharmaceuticals
ACADIA Pharma: Reviewing The Sell-Off And Valuation
Core Labs Does It Again
Lipocine Vs. Antares: Who Wins?
PCSK9 Drugs Are Overhyped - Why Amgen's Fourier CVOT Will Disappoint
Insider Buying At Antares Pharma
Nuance: Why Is Icahn Dumping Shares?
Aerie Pharma: Significantly Derisked
Don't Buy Boeing; Buy Its Supplier Instead
Core Labs: Primed To Outperform The Oil Services Sector
Generic EpiPen: What's The Hold-Up?
Recent Setbacks Have Duchenne Investors On Edge
Valuing Acadia Pharmaceuticals
There's A High Risk Catalyst On Catabasis' Horizon
Esperion Therapeutics: Too Much Uncertainty To Go Long
Nuance Is An Easy Buy - With One Caveat (Part 3)
Nuance Is An Easy Buy - With One Caveat (Part 2)
Nuance Is An Easy Buy - With One Caveat (Part 1)
Why Google Now And Other Personal Assistants Demand Investor Attention
Catalyst Packed Quarter Looming For Antares Pharma
The Oil Service Sector Is Ripe For Bottom Fishing
Unilife Puts Itself Up For Sale - Is The Stock A Buy Now?
Aerie Pharma: What To Do After Shares Rocket Higher?
Understanding The Volatility In Esperion Therapeutics
Antares Pharma: Why I'm Still Long
The Race To Cure Duchenne Muscular Dystrophy - An Investor's Guide
Aerie Pharma: Catalyst Packed Quarter Looming
A Letter To Antares Pharma's Board Of Directors
Wide Moat And Attractive Valuation Makes Hexcel A Buy
Tailwinds Forming For Nuance
Unilife Q3 2015 Earnings Preview
Aerie Pharma: Was Rocket 1 Really A Failure?